de Reijke T - Search Results

1

The Prostate Cancer gene 3 assay: indications for use in clinical practice.

Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A. Schilling D, et al. Among authors: de la taille a, de reijke t. BJU Int. 2010 Feb;105(4):452-5. doi: 10.1111/j.1464-410X.2009.09085.x. Epub 2009 Nov 20. BJU Int. 2010. PMID: 19930176 Review.

2

Biological half-life of prostate-specific antigen after radical prostatectomy.

van Straalen JP, Bossens MM, de Reijke TM, Sanders GT. van Straalen JP, et al. Among authors: de reijke tm. Eur J Clin Chem Clin Biochem. 1994 Feb;32(2):53-5. doi: 10.1515/cclm.1994.32.2.53. Eur J Clin Chem Clin Biochem. 1994. PMID: 7516193

3

Incidental carcinoma of the prostate.

van Andel G, Vleeming R, Kurth K, de Reijke TM. van Andel G, et al. Among authors: de reijke tm. Semin Surg Oncol. 1995 Jan-Feb;11(1):36-45. doi: 10.1002/ssu.2980110106. Semin Surg Oncol. 1995. PMID: 7538693 Review.

4

Kinetics of prostate-specific antigen after manipulation of the prostate.

Bossens MM, Van Straalen JP, De Reijke TM, Kurth KH, Sanders GT. Bossens MM, et al. Among authors: de reijke tm. Eur J Cancer. 1995;31A(5):682-5. doi: 10.1016/0959-8049(95)00016-c. Eur J Cancer. 1995. PMID: 7543764

5

Does prostate-specific antigen density alter decision making on biopsy?

Vleeming R, de Craen AJ, de Reijke TM, van Andel G, Kurth KH. Vleeming R, et al. Among authors: de craen aj, de reijke tm. Eur Urol. 1996;29(1):10-14. doi: 10.1159/000473710. Eur Urol. 1996. PMID: 8821683

6

[The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate].

Hoefman E, Hulshof MC, de Reijke TM, Bruijnes E, Redekop WK, van Straalen JP. Hoefman E, et al. Among authors: de reijke tm. Ned Tijdschr Geneeskd. 1998 May 16;142(20):1142-6. Ned Tijdschr Geneeskd. 1998. PMID: 9623236 Dutch.

7

Considerations regarding prostate biopsies.

Beerlage HP, de Reijke TM, de la Rosette JJ. Beerlage HP, et al. Among authors: de reijke tm, de la rosette jj. Eur Urol. 1998 Oct;34(4):303-12. doi: 10.1159/000019746. Eur Urol. 1998. PMID: 9748677 Review.

8

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH. Rademaker-Lakhai JM, et al. Clin Cancer Res. 2005 Mar 1;11(5):1854-62. doi: 10.1158/1078-0432.CCR-04-1534. Clin Cancer Res. 2005. PMID: 15756010 Clinical Trial.

9

Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol.

de la Rosette JJ, Wink MH, Mamoulakis C, Wondergem N, ten Kate FJ, Zwinderman K, de Reijke TM, Wijkstra H. de la Rosette JJ, et al. J Urol. 2009 Oct;182(4):1329-36. doi: 10.1016/j.juro.2009.06.037. Epub 2009 Aug 15. J Urol. 2009. PMID: 19683269 Clinical Trial.

10

Trends in epidemiology and treatment of upper urinary tract tumours in the Netherlands 1995-2005: an analysis of PALGA, the Dutch national histopathology registry.

Cauberg EC, Salomons MA, Kümmerlin IP, de Reijke TM, Zwinderman AH, de la Rosette JJ, Kate FJ, Laguna Pes MP. Cauberg EC, et al. BJU Int. 2010 Apr;105(7):922-7. doi: 10.1111/j.1464-410X.2009.08889.x. Epub 2009 Oct 5. BJU Int. 2010. PMID: 19804428

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

273 results

Search Page